

Rec'd PCT/PTO

7 JUL 2005

#5

Express Mail No.: EV 452 775 753 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Senter et al.

Confirmation No. 7034

Application No.: 10/522,911 (U.S. National  
Stage of PCT/US03/24209, filed July 31, 2003)

Group Art Unit: TBA

Filed: July 31, 2003

Examiner: TBA

For: DRUG CONJUGATES AND THEIR  
USE FOR TREATING CANCER, AN  
AUTOIMMUNE DISEASE OR AN  
INFECTIOUS DISEASE

Attorney Docket No.: 9632-093-999  
(CAM: 407517-999091)

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56 and 1.97**

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or may be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to References **A01-A25**, **B01-B10** and **C01-C14**, which are listed on the accompanying Form PTO-1449 entitled "List of References Cited By Applicant." Identification of the listed references is not to be construed as an admission that such references are available as "prior art" against the subject application.

Copies of references **B01-B10** and **C01-C14** are submitted herewith. Copies of references **A01-A25** (each being a U.S. patent or patent publication) are not submitted herewith pursuant to waiver of the requirement under 37 C.F.R. § 1.98(a)(2)(i) for submitting a copy of each cited U.S. patent or patent publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 U.S.C. § 371 after June 30, 2003.

Applicants request that the Examiner review the references identified on the attached Form PTO-1449, and that they be made of record in the file history of the above-identified application.

As this Information Disclosure Statement is being filed pursuant to 37 C.F.R. § 1.97(b)(3), before the mailing date of a first Office Action on the merits, Applicants estimate that no fee is required. Should a fee be required, the Commissioner is authorized to charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Date: July 7, 2005

  
Adriane M. Antler (Reg. No. 32,605)

**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, New York 10017-6702  
(212) 326-3939

Enclosures

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	ATTY. DOCKET NO. <b>9632-093-999</b>	APPLICATION NO. <b>10/522,911</b>
	APPLICANT <b>Senter et al.</b>	
	FILING DATE <b>July 31, 2003</b>	GROUP <b>TBD</b>

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	4,414,205	11/08/1983	Pettit			
	A02	4,816,444	03/28/1989	Pettit et al.			
	A03	4,879,278	11/07/1989	Pettit et al.			
	A04	4,978,744	12/18/1990	Pettit et al.			
	A05	5,410,024	04/25/1995	Pettit et al.			
	A06	5,521,284	05/28/1996	Pettit et al.			
	A07	5,530,097	06/25/1996	Pettit et al.			
	A08	5,554,725	09/10/1996	Pettit			
	A09	5,599,902	02/04/1997	Pettit et al.			
	A10	5,635,483	06/03/1997	Pettit et al.			
	A11	5,654,399	08/05/1997	Sakakibara et al.			
	A12	5,663,149	09/02/1997	Pettit et al.			
	A13	5,665,860	09/09/1997	Pettit et al.			
	A14	5,741,892	04/21/1998	Barlozzari et al.			
	A15	5,767,236	06/16/1998	Kim et al.			
	A16	5,767,237	06/16/1998	Sakakibara et al.			
	A17	5,780,588	07/14/1998	Pettit et al.			
	A18	5,840,699	11/24/1998	Sakakibara et al.			
	A19	6,004,934	12/21/1999	Sakakibara et al.			
	A20	6,034,065	03/07/2000	Pettit et al.			
	A21	6,124,431	09/26/2000	Sakakibara et al.			
	A22	6,162,930	12/19/2000	Pinney et al.			
	A23	6,239,104	05/29/2001	Pettit et al.			
	A24	6,342,221	01/29/2002	Thorpe et al.			
	A25	2001/0018422	08/30/2001	Ritter et al.			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	WO 93/03054	02/18/1993	PCT (with English abstract)				
	B02	WO 95/09864	04/13/1995	PCT (with English abstract)				
	B03	WO 96/14856	5/23/1996	PCT				
	B04	WO 96/33212	10/24/1996	PCT (with English abstract)				
	B05	WO 01/18032	03/15/2001	PCT				
	B06	WO 2004/010957	02/05/2004	PCT				
	B07	EP 0 598 129	05/25/1994	EPO				

	B08	EP 0 695 757	02/07/1996	EPO				
	B09	EP 0 695 758	02/07/1996	EPO				
	B10	EP 0 695 759	02/07/1996	EPO				

**OTHER REFERENCES** *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	C01	Bowman et al. 1950, "N-substituted amino-acids. Part I. A new method of preparation of dimethylamino-acids," J. Chem. Soc.:1342-1351
	C02	Miyazaki et al., 1995, "Synthesis and antitumor activity of novel dolastatin 10 analogs," Chem. Pharm. Bull. (Tokyo) 43(10):1706-1718
	C03	Pettit et al., 1995, "Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications," Anticancer Drug Des. 10(7):529-544
	C04	Pettit, 1998, "Antineoplastic agents 365. Dolastatin 10 SAR probes," Anticancer Drug Des. 13(4):243-277
	C05	Petit et al., 1996, "Dolastatins. 23: Stereospecific synthesis of dolaisoleuine," J. Chem Soc. Perkin. Trans. 1:853-858
	C06	Pettit et al., 1996, "Dolastatins 24. Synthesis of (-)-dolastatin 10. X-ray molecular structure of N,N-dimethylvalyl-valyl-dolaisoleuine, tert-butyl ester," J. Chem. Soc. Perk Trans. 1:859-863
	C07	Pettit et al., 1994, "The Dolastatins. 17. Synthesis of dolaproine and related diastereoisomers," J. Org. Chem. 59(21):6287-6295
	C08	Pettit et al., 1996, "The Dolastatins. 18. Stereospecific synthesis of dolaproine," Synthesis 6:719-725
	C09	Pettit et al., 1994, "The Dolastatins. 19. Synthesis of dolaisoleuine," J. Org. Chem. 59(7):1796-1800
	C10	Pettit, 1997, "The Dolastatins," (reprint) Springer-Verlag, New York 70:1-79
	C11	Shioiri et al., 1993, "Stereoselective synthesis of dolastatin 10 and its congeners," Tetrahedron 49(9):1913-1924
	C12	Toki et al., "Cures and regressions of established tumor xenographs with monoclonal antibody," 223 <sup>rd</sup> ACS Meeting, Orlando FL, April 7-11, 2002, Abstract 147
	C13	Tomioka et al., 1991, "An expeditious synthesis of dolastatin 10," Tetrahedron Letters 32(21):2395-2398
	C14	International search report of International Application No. PCT/US03/24209, 16 Apr 2004

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.